🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 133 (from laksa139)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa133.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://ausvaxsafety.org.au/covid-19-vaccine-side-effects\')), getAhrefsUnparsedNoserviceFromURL(\'https://ausvaxsafety.org.au/covid-19-vaccine-side-effects\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/ausvaxsafety.org.au\/covid-19-vaccine-side-effects","crawl_time":1776095547,"first_indexed_time":1764829728,"http_code":200,"src_unparsed":"au,org,ausvaxsafety!\/covid-19-vaccine-side-effects s443","src_root_hash":"15465543789884751333","history_drop_reason":null,"meta_title":"COVID-19 vaccine side effects | AusVaxSafety","meta_descriptions":["More than 60 million doses of COVID-19 vaccines have now been administered in Australia. The safety of these vaccines is monitored on an ongoing basis and while there are some commonly reported side effects, reports of serious side effects are extremely rare. Common side effectsLike all medicines used in Australia, COVID-19 vaccines can cause mild side effects, but not everyone gets them. Most side effects are mild and short-lived, with the vast majority of people affected recovering within 3 days. Common side effects include:"],"attrs_boilerpipe_text":"More than 60 million doses of COVID-19 vaccines have now been administered in Australia. The safety of these vaccines is monitored on an ongoing basis and while there are some commonly reported side effects, reports of serious side effects are extremely rare.\n \nCommon side effects\nLike all medicines used in Australia, COVID-19 vaccines can cause mild side effects, but not everyone gets them. Most side effects are mild and short-lived, with the vast majority of people affected recovering within 3 days. Common side effects include:\npain at injection site\nfeeling tired\nheadache\naches and pain\nfever and chills\nYou can take pain relief medication such as paracetamol to help relieve these symptoms.\nAccess the latest COVID-19 vaccine short-term common side effects data here\nIt can take up to\n12 days after the first dose\n(link is external)\nof the vaccine for your body to produce antibodies to partially protect you, and\n7–14 days after the second dose\n(link is external)\nto reach the optimal level of protection provided by the vaccine. You cannot catch COVID-19 from getting your vaccine; however, if you develop COVID-19-like symptoms any time after your vaccination, it is important that you still get tested and follow public health advice. A booster dose is recommended\n3 months after your second dose\n(link is external)\nto make sure the protection from the first 2 doses is even stronger and longer lasting.\n \nExtremely rare side effects\nSerious or allergic reactions to vaccines are extremely rare. Although serious allergic reactions usually occur within 15 minutes of receiving a vaccine, there are some very rare conditions that have been linked to COVID-19 vaccines that can occur later after vaccination.\n \nBlood clots (Thrombosis with thrombocytopenia syndrome – TTS)\nThrombosis with thrombocytopenia syndrome (TTS) has been found to be causally associated with the AstraZeneca COVID-19 vaccine. This condition is very rare, with\n2 cases out of every 100,000 people\n(link is external)\nafter a first dose AstraZeneca vaccine and 3 cases out of every million people after a second dose of  AstraZeneca vaccine reported in Australia.\nTTS involves the formation of blood clots (thrombosis) by platelets in body places where blood clots should not occur, such as the brain, abdomen, chest and legs, preventing blood flowing normally through those parts of the body. Because the platelets are used up in the formation of these clots, it leads to a decrease in platelets (thrombocytopenia) in the bloodstream, preventing them from doing their normal function. Thrombocytopenia can lead to excessive bleeding if blood cannot form clots where it is needed.  \nSymptoms of TTS most commonly develop 4 to 30 days after an adenovector viral vaccine such as the AstraZeneca vaccine. The condition is not found to be associated with mRNA vaccines such as Pfizer and Moderna vaccines. \nEarly treatment for TTS can prevent serious complications. It is therefore important for people with early symptoms of TTS to get medical attention as soon as possible. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have:\nsevere or persistent headache that does not go away after taking pain relief medication\nblurred vision, loss of power or sensation, confusion or seizures\nshortness of breath\nabdominal pain that does not go away after taking pain relief medication\nchest pain\nleg pain or leg swelling\nunusual bruising or pinpoint spots (petechiae) on skin that can not be explained from trauma.\nMore detailed information on TTS is available at the links below:\nDepartment of Health, Disability and Ageing AstraZeneca COVID-19 vaccination information sheet\n(link is external)\nReported cases of TTS in Australia – TGA COVID-19 weekly vaccine safety reports\n(link is external)\nJoint statement from the Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on TTS and the use of COVID-19 Vaccine AstraZeneca\n(link is external)\nWeighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca\n(link is external)\nAusVaxSafety Adverse event of special interest (AESI) follow-up program - TTS\n \nHeart inflammation (myocarditis and pericarditis)\nIn rare instances, myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) have been reported by individuals after receiving an mRNA COVID-19 vaccine – Pfizer or Moderna. \nMost cases typically happen within 10 days of vaccination and occur more commonly after the second dose in men aged under 30 years. Most people have mild symptoms and recover well. In Australia,\n1–2 cases out of every 100,000 people\n(link is external)\nafter receiving the Pfizer vaccine have been reported.\nContact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have:\nchest pain\npressure or discomfort in the chest\nirregular, skipped heartbeats or ‘fluttering’\nfainting\nshortness of breath\npain when breathing.\nMore detailed information on myocarditis and pericarditis is available at the links below:\nDepartment of Health, Disability and Ageing guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines\n(link is external)\nReported cases of myocarditis and pericarditis in Australia – TGA COVID-19 weekly vaccine safety reports\n(link is external)\n \nCOVID-19 Vaccine Side Effects Symptom Checker\nIf you think you may be experiencing side effects following your COVID-19 vaccination, you can check these and get information on what to do next on the healthdirect COVID-19 vaccine Side Effects Symptom Checker below.\nhealthdirect COVID-19 vaccine Side Effects Symptom Checker\n(link is external)\n \nLast updated May 2025","attrs_markdown":"[Skip to main content](https:\/\/ausvaxsafety.org.au\/covid-19-vaccine-side-effects#main-content)\n\nAustralia’s active vaccine safety system\n\n- [![](https:\/\/ausvaxsafety.org.au\/themes\/ausvax\/images\/logosmall2x.png)](http:\/\/www.ncirs.org.au\/)\n- [![](https:\/\/ausvaxsafety.org.au\/themes\/ausvax\/images\/ausvax2x.png)](https:\/\/ausvaxsafety.org.au\/)\n- [![](https:\/\/ausvaxsafety.org.au\/themes\/ausvax\/images\/paeds2x.png)](http:\/\/www.paeds.edu.au\/)\n\n[![](https:\/\/ausvaxsafety.org.au\/themes\/ausvax\/images\/logo2x.png)](https:\/\/ausvaxsafety.org.au\/)\n\n## Secondary Menu\n- [Contact](https:\/\/ausvaxsafety.org.au\/contact-us)\n\n![](https:\/\/ausvaxsafety.org.au\/themes\/ausvax\/images\/logo2x.png)\n\n- [About us](https:\/\/ausvaxsafety.org.au\/about-us)\n- [Vaccine safety surveillance](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance)\n  - [How vaccine safety surveillance works](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/how-vaccine-safety-surveillance-works)\n  - [How AusVaxSafety works](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/how-ausvaxsafety-works)\n  - [Information for immunisation providers](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/information-immunisation-providers)\n  - [Information for immunisation recipients](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/information-immunisation-recipients)\n  - [Publications](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/publications)\n- [Vaccine safety data](https:\/\/ausvaxsafety.org.au\/safety-data)\n  - [COVID-19 vaccines](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/covid-19-vaccines)\n  - [Influenza vaccines](https:\/\/ausvaxsafety.org.au\/safety-data\/influenza-vaccine)\n  - [Mpox (monkeypox) vaccine](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/mpox-monkeypox-vaccine)\n  - [National Immunisation Program schedule vaccines](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/national-immunisation-program-schedule-vaccines)\n  - [Nirsevimab](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/nirsevimab)\n  - [RSV vaccines](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/rsv-vaccines)\n  - [Vaccine safety in Australia AusVaxSafety summary reports](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/vaccine-safety-australia-ausvaxsafety-summary-reports)\n- [News & events](https:\/\/ausvaxsafety.org.au\/news-events)\n- [Resources](https:\/\/ausvaxsafety.org.au\/resources)\n- [Contact](https:\/\/ausvaxsafety.org.au\/contact-us)\n- [![](https:\/\/themes\/ausvax\/images\/ausvaxmobile.png)](http:\/\/ncirs.dev.my.id\/our-work\/ausvaxsafety)\n- [![](https:\/\/themes\/ausvax\/images\/paedsmobile.png)](http:\/\/www.paeds.edu.au\/)\n\n## Main navigation\n- [About us](https:\/\/ausvaxsafety.org.au\/about-us)\n- [Vaccine safety surveillance](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance)\n  - [How vaccine safety surveillance works](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/how-vaccine-safety-surveillance-works)\n  - [How AusVaxSafety works](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/how-ausvaxsafety-works)\n  \n  - [Information for immunisation providers](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/information-immunisation-providers)\n  - [Information for immunisation recipients](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/information-immunisation-recipients)\n  \n  - [Publications](https:\/\/ausvaxsafety.org.au\/vaccine-safety-surveillance\/publications)\n- [Vaccine safety data](https:\/\/ausvaxsafety.org.au\/safety-data)\n  - [COVID-19 vaccines](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/covid-19-vaccines)\n  - [Influenza vaccines](https:\/\/ausvaxsafety.org.au\/safety-data\/influenza-vaccine)\n  \n  - [Mpox (monkeypox) vaccine](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/mpox-monkeypox-vaccine)\n  - [National Immunisation Program schedule vaccines](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/national-immunisation-program-schedule-vaccines)\n  \n  - [Nirsevimab](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/nirsevimab)\n  - [RSV vaccines](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/rsv-vaccines)\n  \n  - [Vaccine safety in Australia AusVaxSafety summary reports](https:\/\/ausvaxsafety.org.au\/vaccine-safety-data\/vaccine-safety-australia-ausvaxsafety-summary-reports)\n- [News & events](https:\/\/ausvaxsafety.org.au\/news-events)\n- [Resources](https:\/\/ausvaxsafety.org.au\/resources)\n\n# COVID-19 vaccine side effects\nMore than 60 million doses of COVID-19 vaccines have now been administered in Australia. The safety of these vaccines is monitored on an ongoing basis and while there are some commonly reported side effects, reports of serious side effects are extremely rare.\n\n### Common side effects\nLike all medicines used in Australia, COVID-19 vaccines can cause mild side effects, but not everyone gets them. Most side effects are mild and short-lived, with the vast majority of people affected recovering within 3 days. Common side effects include:\n\n- pain at injection site\n- feeling tired\n- headache\n- aches and pain\n- fever and chills\n\nYou can take pain relief medication such as paracetamol to help relieve these symptoms.\n\n[Access the latest COVID-19 vaccine short-term common side effects data here](https:\/\/ausvaxsafety.org.au\/safety-data\/covid-19-vaccines)\n\nIt can take up to [**12 days after the first dose**](https:\/\/www.health.gov.au\/initiatives-and-programs\/covid-19-vaccines\/getting-your-vaccination\/after) of the vaccine for your body to produce antibodies to partially protect you, and [**7–14 days after the second dose**](https:\/\/www.health.gov.au\/initiatives-and-programs\/covid-19-vaccines\/getting-your-vaccination\/after) to reach the optimal level of protection provided by the vaccine. You cannot catch COVID-19 from getting your vaccine; however, if you develop COVID-19-like symptoms any time after your vaccination, it is important that you still get tested and follow public health advice. A booster dose is recommended [**3 months after your second dose**](https:\/\/www.health.gov.au\/initiatives-and-programs\/covid-19-vaccines\/getting-your-vaccination\/booster-doses) to make sure the protection from the first 2 doses is even stronger and longer lasting.\n\n### Extremely rare side effects\nSerious or allergic reactions to vaccines are extremely rare. Although serious allergic reactions usually occur within 15 minutes of receiving a vaccine, there are some very rare conditions that have been linked to COVID-19 vaccines that can occur later after vaccination.\n\n##### Blood clots (Thrombosis with thrombocytopenia syndrome – TTS)\nThrombosis with thrombocytopenia syndrome (TTS) has been found to be causally associated with the AstraZeneca COVID-19 vaccine. This condition is very rare, with[**2 cases out of every 100,000 people**](https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report\/current) after a first dose AstraZeneca vaccine and 3 cases out of every million people after a second dose of AstraZeneca vaccine reported in Australia.\n\nTTS involves the formation of blood clots (thrombosis) by platelets in body places where blood clots should not occur, such as the brain, abdomen, chest and legs, preventing blood flowing normally through those parts of the body. Because the platelets are used up in the formation of these clots, it leads to a decrease in platelets (thrombocytopenia) in the bloodstream, preventing them from doing their normal function. Thrombocytopenia can lead to excessive bleeding if blood cannot form clots where it is needed.\n\nSymptoms of TTS most commonly develop 4 to 30 days after an adenovector viral vaccine such as the AstraZeneca vaccine. The condition is not found to be associated with mRNA vaccines such as Pfizer and Moderna vaccines.\n\nEarly treatment for TTS can prevent serious complications. It is therefore important for people with early symptoms of TTS to get medical attention as soon as possible. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have:\n\n- severe or persistent headache that does not go away after taking pain relief medication\n- blurred vision, loss of power or sensation, confusion or seizures\n- shortness of breath\n- abdominal pain that does not go away after taking pain relief medication\n- chest pain\n- leg pain or leg swelling\n- unusual bruising or pinpoint spots (petechiae) on skin that can not be explained from trauma.\n\nMore detailed information on TTS is available at the links below:\n\n- [**Department of Health, Disability and Ageing AstraZeneca COVID-19 vaccination information sheet**](https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-information-on-vaxzevria-astrazeneca-covid-19-vaccine)\n- [**Reported cases of TTS in Australia – TGA COVID-19 weekly vaccine safety reports**](https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report)\n- [**Joint statement from the Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on TTS and the use of COVID-19 Vaccine AstraZeneca**](https:\/\/www.health.gov.au\/news\/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca)\n- [**Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca**](https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca)\n- [**AusVaxSafety Adverse event of special interest (AESI) follow-up program - TTS**](https:\/\/ausvaxsafety.org.au\/aesi-follow-program\/study-arm-1-thrombosis-thrombocytopenia-syndrome)\n##### Heart inflammation (myocarditis and pericarditis)\nIn rare instances, myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) have been reported by individuals after receiving an mRNA COVID-19 vaccine – Pfizer or Moderna.\n\nMost cases typically happen within 10 days of vaccination and occur more commonly after the second dose in men aged under 30 years. Most people have mild symptoms and recover well. In Australia, [**1–2 cases out of every 100,000 people**](https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report\/current) after receiving the Pfizer vaccine have been reported.\n\nContact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have:\n\n- chest pain\n- pressure or discomfort in the chest\n- irregular, skipped heartbeats or ‘fluttering’\n- fainting\n- shortness of breath\n- pain when breathing.\n\nMore detailed information on myocarditis and pericarditis is available at the links below:\n\n- [**Department of Health, Disability and Ageing guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines**](https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-guidance-on-myocarditis-and-pericarditis-after-mrna-covid-19-vaccines)\n- [**Reported cases of myocarditis and pericarditis in Australia – TGA COVID-19 weekly vaccine safety reports**](https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report)\n### COVID-19 Vaccine Side Effects Symptom Checker\nIf you think you may be experiencing side effects following your COVID-19 vaccination, you can check these and get information on what to do next on the healthdirect COVID-19 vaccine Side Effects Symptom Checker below.\n\n[healthdirect COVID-19 vaccine Side Effects Symptom Checker](https:\/\/www.healthdirect.gov.au\/covid-19-vaccine-side-effect-checker)\n\n**Last updated May 2025**\n\nShare this page:\n\n### News & events\n[All news & events](https:\/\/ausvaxsafety.org.au\/covid-19-vaccine-side-effects)\n\n[05 March 2026 \\| News New LP.8.1 COVID-19 vaccines well tolerated, new AusVaxSafety data show](https:\/\/ausvaxsafety.org.au\/new-lp81-covid-19-vaccines-well-tolerated-new-ausvaxsafety-data-show)\n\n[14 July 2025 \\| News Fewer adverse events reported following NIP pneumococcal vaccine change](https:\/\/ausvaxsafety.org.au\/fewer-adverse-events-reported-following-nip-pneumococcal-vaccine-change)\n\n[03 June 2025 \\| News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations](https:\/\/ausvaxsafety.org.au\/new-ausvaxsafety-data-confirms-abrysvo-rsv-vaccine-well-tolerated-during-pregnancy-adverse-events)\n\n[18 May 2025 \\| News 2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination](https:\/\/ausvaxsafety.org.au\/2025-australian-flu-season-who-should-get-flu-shot-which-vaccines-are-available-and-what-expect)\n\n## Navigate\n- [Contact Us](https:\/\/ausvaxsafety.org.au\/contact-us)\n- [Disclaimer](https:\/\/ausvaxsafety.org.au\/disclaimer)\n- [Privacy](https:\/\/ausvaxsafety.org.au\/privacy)\n- [Accessibility](https:\/\/ausvaxsafety.org.au\/accessibility)\n\n*AusVaxSafety receives funding from the Australian Government*\n\nNCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 \\| Fax (612) 9845 1418 \\| ABN 53 188 579 090\n\nWe acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.\n\nCopyright © 2026 AusVaxSafety. All rights reserved\n\n[![vaccine](https:\/\/ausvaxsafety.org.au\/sites\/default\/files\/inline-images\/vaccine-safety-net-logo-2.png)](https:\/\/vaccinesafetynet.org\/)\n\nOur website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.\n\n## Subscribe to our newsletter for immunisation professionals\nStay updated with the latest from NCIRS\n\n- [Contact Us](https:\/\/ausvaxsafety.org.au\/contact-us)\n- [Disclaimer](https:\/\/ausvaxsafety.org.au\/disclaimer)\n- [Privacy](https:\/\/ausvaxsafety.org.au\/privacy)\n\n- [Accessibility](https:\/\/ausvaxsafety.org.au\/accessibility)\n\n##### Subscribe to our newsletter for immunisation professionals\nStay updated with the latest from ausvax\n\nNCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 \\| Fax (612) 9845 1418 \\| ABN 53 188 579 090\n\n![](https:\/\/ausvaxsafety.org.au\/sites\/default\/files\/inline-images\/vaccine-safety-net-logo-2.png)\n\nOur website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.\n\nWe acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.","attrs_readable_markdown":"More than 60 million doses of COVID-19 vaccines have now been administered in Australia. The safety of these vaccines is monitored on an ongoing basis and while there are some commonly reported side effects, reports of serious side effects are extremely rare.\n\n### Common side effects\nLike all medicines used in Australia, COVID-19 vaccines can cause mild side effects, but not everyone gets them. Most side effects are mild and short-lived, with the vast majority of people affected recovering within 3 days. Common side effects include:\n\n- pain at injection site\n- feeling tired\n- headache\n- aches and pain\n- fever and chills\n\nYou can take pain relief medication such as paracetamol to help relieve these symptoms.\n\n[Access the latest COVID-19 vaccine short-term common side effects data here](https:\/\/ausvaxsafety.org.au\/safety-data\/covid-19-vaccines)\n\nIt can take up to [**12 days after the first dose**](https:\/\/www.health.gov.au\/initiatives-and-programs\/covid-19-vaccines\/getting-your-vaccination\/after) of the vaccine for your body to produce antibodies to partially protect you, and [**7–14 days after the second dose**](https:\/\/www.health.gov.au\/initiatives-and-programs\/covid-19-vaccines\/getting-your-vaccination\/after) to reach the optimal level of protection provided by the vaccine. You cannot catch COVID-19 from getting your vaccine; however, if you develop COVID-19-like symptoms any time after your vaccination, it is important that you still get tested and follow public health advice. A booster dose is recommended [**3 months after your second dose**](https:\/\/www.health.gov.au\/initiatives-and-programs\/covid-19-vaccines\/getting-your-vaccination\/booster-doses) to make sure the protection from the first 2 doses is even stronger and longer lasting.\n\n### Extremely rare side effects\nSerious or allergic reactions to vaccines are extremely rare. Although serious allergic reactions usually occur within 15 minutes of receiving a vaccine, there are some very rare conditions that have been linked to COVID-19 vaccines that can occur later after vaccination.\n\n##### Blood clots (Thrombosis with thrombocytopenia syndrome – TTS)\nThrombosis with thrombocytopenia syndrome (TTS) has been found to be causally associated with the AstraZeneca COVID-19 vaccine. This condition is very rare, with[**2 cases out of every 100,000 people**](https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report\/current) after a first dose AstraZeneca vaccine and 3 cases out of every million people after a second dose of AstraZeneca vaccine reported in Australia.\n\nTTS involves the formation of blood clots (thrombosis) by platelets in body places where blood clots should not occur, such as the brain, abdomen, chest and legs, preventing blood flowing normally through those parts of the body. Because the platelets are used up in the formation of these clots, it leads to a decrease in platelets (thrombocytopenia) in the bloodstream, preventing them from doing their normal function. Thrombocytopenia can lead to excessive bleeding if blood cannot form clots where it is needed.\n\nSymptoms of TTS most commonly develop 4 to 30 days after an adenovector viral vaccine such as the AstraZeneca vaccine. The condition is not found to be associated with mRNA vaccines such as Pfizer and Moderna vaccines.\n\nEarly treatment for TTS can prevent serious complications. It is therefore important for people with early symptoms of TTS to get medical attention as soon as possible. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have:\n\n- severe or persistent headache that does not go away after taking pain relief medication\n- blurred vision, loss of power or sensation, confusion or seizures\n- shortness of breath\n- abdominal pain that does not go away after taking pain relief medication\n- chest pain\n- leg pain or leg swelling\n- unusual bruising or pinpoint spots (petechiae) on skin that can not be explained from trauma.\n\nMore detailed information on TTS is available at the links below:\n\n- [**Department of Health, Disability and Ageing AstraZeneca COVID-19 vaccination information sheet**](https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-information-on-vaxzevria-astrazeneca-covid-19-vaccine)\n- [**Reported cases of TTS in Australia – TGA COVID-19 weekly vaccine safety reports**](https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report)\n- [**Joint statement from the Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on TTS and the use of COVID-19 Vaccine AstraZeneca**](https:\/\/www.health.gov.au\/news\/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca)\n- [**Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca**](https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca)\n- [**AusVaxSafety Adverse event of special interest (AESI) follow-up program - TTS**](https:\/\/ausvaxsafety.org.au\/aesi-follow-program\/study-arm-1-thrombosis-thrombocytopenia-syndrome)\n##### Heart inflammation (myocarditis and pericarditis)\nIn rare instances, myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) have been reported by individuals after receiving an mRNA COVID-19 vaccine – Pfizer or Moderna.\n\nMost cases typically happen within 10 days of vaccination and occur more commonly after the second dose in men aged under 30 years. Most people have mild symptoms and recover well. In Australia, [**1–2 cases out of every 100,000 people**](https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report\/current) after receiving the Pfizer vaccine have been reported.\n\nContact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have:\n\n- chest pain\n- pressure or discomfort in the chest\n- irregular, skipped heartbeats or ‘fluttering’\n- fainting\n- shortness of breath\n- pain when breathing.\n\nMore detailed information on myocarditis and pericarditis is available at the links below:\n\n- [**Department of Health, Disability and Ageing guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines**](https:\/\/www.health.gov.au\/resources\/publications\/covid-19-vaccination-guidance-on-myocarditis-and-pericarditis-after-mrna-covid-19-vaccines)\n- [**Reported cases of myocarditis and pericarditis in Australia – TGA COVID-19 weekly vaccine safety reports**](https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report)\n### COVID-19 Vaccine Side Effects Symptom Checker\nIf you think you may be experiencing side effects following your COVID-19 vaccination, you can check these and get information on what to do next on the healthdirect COVID-19 vaccine Side Effects Symptom Checker below.\n\n[healthdirect COVID-19 vaccine Side Effects Symptom Checker](https:\/\/www.healthdirect.gov.au\/covid-19-vaccine-side-effect-checker)\n\n**Last updated May 2025**","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

5 days ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0.2 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://ausvaxsafety.org.au/covid-19-vaccine-side-effects
Last Crawled	2026-04-13 15:52:27 (5 days ago)
First Indexed	2025-12-04 06:28:48 (4 months ago)
HTTP Status Code	200
Meta Title	COVID-19 vaccine side effects \| AusVaxSafety
Meta Description	More than 60 million doses of COVID-19 vaccines have now been administered in Australia. The safety of these vaccines is monitored on an ongoing basis and while there are some commonly reported side effects, reports of serious side effects are extremely rare. Common side effectsLike all medicines used in Australia, COVID-19 vaccines can cause mild side effects, but not everyone gets them. Most side effects are mild and short-lived, with the vast majority of people affected recovering within 3 days. Common side effects include:
Meta Canonical	null
Boilerpipe Text	More than 60 million doses of COVID-19 vaccines have now been administered in Australia. The safety of these vaccines is monitored on an ongoing basis and while there are some commonly reported side effects, reports of serious side effects are extremely rare. Common side effects Like all medicines used in Australia, COVID-19 vaccines can cause mild side effects, but not everyone gets them. Most side effects are mild and short-lived, with the vast majority of people affected recovering within 3 days. Common side effects include: pain at injection site feeling tired headache aches and pain fever and chills You can take pain relief medication such as paracetamol to help relieve these symptoms. Access the latest COVID-19 vaccine short-term common side effects data here It can take up to 12 days after the first dose (link is external) of the vaccine for your body to produce antibodies to partially protect you, and 7–14 days after the second dose (link is external) to reach the optimal level of protection provided by the vaccine. You cannot catch COVID-19 from getting your vaccine; however, if you develop COVID-19-like symptoms any time after your vaccination, it is important that you still get tested and follow public health advice. A booster dose is recommended 3 months after your second dose (link is external) to make sure the protection from the first 2 doses is even stronger and longer lasting. Extremely rare side effects Serious or allergic reactions to vaccines are extremely rare. Although serious allergic reactions usually occur within 15 minutes of receiving a vaccine, there are some very rare conditions that have been linked to COVID-19 vaccines that can occur later after vaccination. Blood clots (Thrombosis with thrombocytopenia syndrome – TTS) Thrombosis with thrombocytopenia syndrome (TTS) has been found to be causally associated with the AstraZeneca COVID-19 vaccine. This condition is very rare, with 2 cases out of every 100,000 people (link is external) after a first dose AstraZeneca vaccine and 3 cases out of every million people after a second dose of AstraZeneca vaccine reported in Australia. TTS involves the formation of blood clots (thrombosis) by platelets in body places where blood clots should not occur, such as the brain, abdomen, chest and legs, preventing blood flowing normally through those parts of the body. Because the platelets are used up in the formation of these clots, it leads to a decrease in platelets (thrombocytopenia) in the bloodstream, preventing them from doing their normal function. Thrombocytopenia can lead to excessive bleeding if blood cannot form clots where it is needed. Symptoms of TTS most commonly develop 4 to 30 days after an adenovector viral vaccine such as the AstraZeneca vaccine. The condition is not found to be associated with mRNA vaccines such as Pfizer and Moderna vaccines. Early treatment for TTS can prevent serious complications. It is therefore important for people with early symptoms of TTS to get medical attention as soon as possible. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have: severe or persistent headache that does not go away after taking pain relief medication blurred vision, loss of power or sensation, confusion or seizures shortness of breath abdominal pain that does not go away after taking pain relief medication chest pain leg pain or leg swelling unusual bruising or pinpoint spots (petechiae) on skin that can not be explained from trauma. More detailed information on TTS is available at the links below: Department of Health, Disability and Ageing AstraZeneca COVID-19 vaccination information sheet (link is external) Reported cases of TTS in Australia – TGA COVID-19 weekly vaccine safety reports (link is external) Joint statement from the Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on TTS and the use of COVID-19 Vaccine AstraZeneca (link is external) Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca (link is external) AusVaxSafety Adverse event of special interest (AESI) follow-up program - TTS Heart inflammation (myocarditis and pericarditis) In rare instances, myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) have been reported by individuals after receiving an mRNA COVID-19 vaccine – Pfizer or Moderna. Most cases typically happen within 10 days of vaccination and occur more commonly after the second dose in men aged under 30 years. Most people have mild symptoms and recover well. In Australia, 1–2 cases out of every 100,000 people (link is external) after receiving the Pfizer vaccine have been reported. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have: chest pain pressure or discomfort in the chest irregular, skipped heartbeats or ‘fluttering’ fainting shortness of breath pain when breathing. More detailed information on myocarditis and pericarditis is available at the links below: Department of Health, Disability and Ageing guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines (link is external) Reported cases of myocarditis and pericarditis in Australia – TGA COVID-19 weekly vaccine safety reports (link is external) COVID-19 Vaccine Side Effects Symptom Checker If you think you may be experiencing side effects following your COVID-19 vaccination, you can check these and get information on what to do next on the healthdirect COVID-19 vaccine Side Effects Symptom Checker below. healthdirect COVID-19 vaccine Side Effects Symptom Checker (link is external) Last updated May 2025
Markdown	[Skip to main content](https://ausvaxsafety.org.au/covid-19-vaccine-side-effects#main-content) Australia’s active vaccine safety system - [![](https://ausvaxsafety.org.au/themes/ausvax/images/logosmall2x.png)](http://www.ncirs.org.au/) - [![](https://ausvaxsafety.org.au/themes/ausvax/images/ausvax2x.png)](https://ausvaxsafety.org.au/) - [![](https://ausvaxsafety.org.au/themes/ausvax/images/paeds2x.png)](http://www.paeds.edu.au/) [![](https://ausvaxsafety.org.au/themes/ausvax/images/logo2x.png)](https://ausvaxsafety.org.au/) ## Secondary Menu - [Contact](https://ausvaxsafety.org.au/contact-us) ![](https://ausvaxsafety.org.au/themes/ausvax/images/logo2x.png) - [About us](https://ausvaxsafety.org.au/about-us) - [Vaccine safety surveillance](https://ausvaxsafety.org.au/vaccine-safety-surveillance) - [How vaccine safety surveillance works](https://ausvaxsafety.org.au/vaccine-safety-surveillance/how-vaccine-safety-surveillance-works) - [How AusVaxSafety works](https://ausvaxsafety.org.au/vaccine-safety-surveillance/how-ausvaxsafety-works) - [Information for immunisation providers](https://ausvaxsafety.org.au/vaccine-safety-surveillance/information-immunisation-providers) - [Information for immunisation recipients](https://ausvaxsafety.org.au/vaccine-safety-surveillance/information-immunisation-recipients) - [Publications](https://ausvaxsafety.org.au/vaccine-safety-surveillance/publications) - [Vaccine safety data](https://ausvaxsafety.org.au/safety-data) - [COVID-19 vaccines](https://ausvaxsafety.org.au/vaccine-safety-data/covid-19-vaccines) - [Influenza vaccines](https://ausvaxsafety.org.au/safety-data/influenza-vaccine) - [Mpox (monkeypox) vaccine](https://ausvaxsafety.org.au/vaccine-safety-data/mpox-monkeypox-vaccine) - [National Immunisation Program schedule vaccines](https://ausvaxsafety.org.au/vaccine-safety-data/national-immunisation-program-schedule-vaccines) - [Nirsevimab](https://ausvaxsafety.org.au/vaccine-safety-data/nirsevimab) - [RSV vaccines](https://ausvaxsafety.org.au/vaccine-safety-data/rsv-vaccines) - [Vaccine safety in Australia AusVaxSafety summary reports](https://ausvaxsafety.org.au/vaccine-safety-data/vaccine-safety-australia-ausvaxsafety-summary-reports) - [News & events](https://ausvaxsafety.org.au/news-events) - [Resources](https://ausvaxsafety.org.au/resources) - [Contact](https://ausvaxsafety.org.au/contact-us) - [![](https://themes/ausvax/images/ausvaxmobile.png)](http://ncirs.dev.my.id/our-work/ausvaxsafety) - [![](https://themes/ausvax/images/paedsmobile.png)](http://www.paeds.edu.au/) ## Main navigation - [About us](https://ausvaxsafety.org.au/about-us) - [Vaccine safety surveillance](https://ausvaxsafety.org.au/vaccine-safety-surveillance) - [How vaccine safety surveillance works](https://ausvaxsafety.org.au/vaccine-safety-surveillance/how-vaccine-safety-surveillance-works) - [How AusVaxSafety works](https://ausvaxsafety.org.au/vaccine-safety-surveillance/how-ausvaxsafety-works) - [Information for immunisation providers](https://ausvaxsafety.org.au/vaccine-safety-surveillance/information-immunisation-providers) - [Information for immunisation recipients](https://ausvaxsafety.org.au/vaccine-safety-surveillance/information-immunisation-recipients) - [Publications](https://ausvaxsafety.org.au/vaccine-safety-surveillance/publications) - [Vaccine safety data](https://ausvaxsafety.org.au/safety-data) - [COVID-19 vaccines](https://ausvaxsafety.org.au/vaccine-safety-data/covid-19-vaccines) - [Influenza vaccines](https://ausvaxsafety.org.au/safety-data/influenza-vaccine) - [Mpox (monkeypox) vaccine](https://ausvaxsafety.org.au/vaccine-safety-data/mpox-monkeypox-vaccine) - [National Immunisation Program schedule vaccines](https://ausvaxsafety.org.au/vaccine-safety-data/national-immunisation-program-schedule-vaccines) - [Nirsevimab](https://ausvaxsafety.org.au/vaccine-safety-data/nirsevimab) - [RSV vaccines](https://ausvaxsafety.org.au/vaccine-safety-data/rsv-vaccines) - [Vaccine safety in Australia AusVaxSafety summary reports](https://ausvaxsafety.org.au/vaccine-safety-data/vaccine-safety-australia-ausvaxsafety-summary-reports) - [News & events](https://ausvaxsafety.org.au/news-events) - [Resources](https://ausvaxsafety.org.au/resources) # COVID-19 vaccine side effects More than 60 million doses of COVID-19 vaccines have now been administered in Australia. The safety of these vaccines is monitored on an ongoing basis and while there are some commonly reported side effects, reports of serious side effects are extremely rare. ### Common side effects Like all medicines used in Australia, COVID-19 vaccines can cause mild side effects, but not everyone gets them. Most side effects are mild and short-lived, with the vast majority of people affected recovering within 3 days. Common side effects include: - pain at injection site - feeling tired - headache - aches and pain - fever and chills You can take pain relief medication such as paracetamol to help relieve these symptoms. [Access the latest COVID-19 vaccine short-term common side effects data here](https://ausvaxsafety.org.au/safety-data/covid-19-vaccines) It can take up to [12 days after the first dose](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-your-vaccination/after) of the vaccine for your body to produce antibodies to partially protect you, and [7–14 days after the second dose](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-your-vaccination/after) to reach the optimal level of protection provided by the vaccine. You cannot catch COVID-19 from getting your vaccine; however, if you develop COVID-19-like symptoms any time after your vaccination, it is important that you still get tested and follow public health advice. A booster dose is recommended [3 months after your second dose](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-your-vaccination/booster-doses) to make sure the protection from the first 2 doses is even stronger and longer lasting. ### Extremely rare side effects Serious or allergic reactions to vaccines are extremely rare. Although serious allergic reactions usually occur within 15 minutes of receiving a vaccine, there are some very rare conditions that have been linked to COVID-19 vaccines that can occur later after vaccination. ##### Blood clots (Thrombosis with thrombocytopenia syndrome – TTS) Thrombosis with thrombocytopenia syndrome (TTS) has been found to be causally associated with the AstraZeneca COVID-19 vaccine. This condition is very rare, with[2 cases out of every 100,000 people](https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report/current) after a first dose AstraZeneca vaccine and 3 cases out of every million people after a second dose of AstraZeneca vaccine reported in Australia. TTS involves the formation of blood clots (thrombosis) by platelets in body places where blood clots should not occur, such as the brain, abdomen, chest and legs, preventing blood flowing normally through those parts of the body. Because the platelets are used up in the formation of these clots, it leads to a decrease in platelets (thrombocytopenia) in the bloodstream, preventing them from doing their normal function. Thrombocytopenia can lead to excessive bleeding if blood cannot form clots where it is needed. Symptoms of TTS most commonly develop 4 to 30 days after an adenovector viral vaccine such as the AstraZeneca vaccine. The condition is not found to be associated with mRNA vaccines such as Pfizer and Moderna vaccines. Early treatment for TTS can prevent serious complications. It is therefore important for people with early symptoms of TTS to get medical attention as soon as possible. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have: - severe or persistent headache that does not go away after taking pain relief medication - blurred vision, loss of power or sensation, confusion or seizures - shortness of breath - abdominal pain that does not go away after taking pain relief medication - chest pain - leg pain or leg swelling - unusual bruising or pinpoint spots (petechiae) on skin that can not be explained from trauma. More detailed information on TTS is available at the links below: - [Department of Health, Disability and Ageing AstraZeneca COVID-19 vaccination information sheet](https://www.health.gov.au/resources/publications/covid-19-vaccination-information-on-vaxzevria-astrazeneca-covid-19-vaccine) - [Reported cases of TTS in Australia – TGA COVID-19 weekly vaccine safety reports](https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report) - [Joint statement from the Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on TTS and the use of COVID-19 Vaccine AstraZeneca](https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca) - [Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca](https://www.health.gov.au/resources/publications/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca) - [AusVaxSafety Adverse event of special interest (AESI) follow-up program - TTS](https://ausvaxsafety.org.au/aesi-follow-program/study-arm-1-thrombosis-thrombocytopenia-syndrome) ##### Heart inflammation (myocarditis and pericarditis) In rare instances, myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) have been reported by individuals after receiving an mRNA COVID-19 vaccine – Pfizer or Moderna. Most cases typically happen within 10 days of vaccination and occur more commonly after the second dose in men aged under 30 years. Most people have mild symptoms and recover well. In Australia, [1–2 cases out of every 100,000 people](https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report/current) after receiving the Pfizer vaccine have been reported. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have: - chest pain - pressure or discomfort in the chest - irregular, skipped heartbeats or ‘fluttering’ - fainting - shortness of breath - pain when breathing. More detailed information on myocarditis and pericarditis is available at the links below: - [Department of Health, Disability and Ageing guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines](https://www.health.gov.au/resources/publications/covid-19-vaccination-guidance-on-myocarditis-and-pericarditis-after-mrna-covid-19-vaccines) - [Reported cases of myocarditis and pericarditis in Australia – TGA COVID-19 weekly vaccine safety reports](https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report) ### COVID-19 Vaccine Side Effects Symptom Checker If you think you may be experiencing side effects following your COVID-19 vaccination, you can check these and get information on what to do next on the healthdirect COVID-19 vaccine Side Effects Symptom Checker below. [healthdirect COVID-19 vaccine Side Effects Symptom Checker](https://www.healthdirect.gov.au/covid-19-vaccine-side-effect-checker) Last updated May 2025 Share this page: ### News & events [All news & events](https://ausvaxsafety.org.au/covid-19-vaccine-side-effects) [05 March 2026 \\| News New LP.8.1 COVID-19 vaccines well tolerated, new AusVaxSafety data show](https://ausvaxsafety.org.au/new-lp81-covid-19-vaccines-well-tolerated-new-ausvaxsafety-data-show) [14 July 2025 \\| News Fewer adverse events reported following NIP pneumococcal vaccine change](https://ausvaxsafety.org.au/fewer-adverse-events-reported-following-nip-pneumococcal-vaccine-change) [03 June 2025 \\| News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations](https://ausvaxsafety.org.au/new-ausvaxsafety-data-confirms-abrysvo-rsv-vaccine-well-tolerated-during-pregnancy-adverse-events) [18 May 2025 \\| News 2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination](https://ausvaxsafety.org.au/2025-australian-flu-season-who-should-get-flu-shot-which-vaccines-are-available-and-what-expect) ## Navigate - [Contact Us](https://ausvaxsafety.org.au/contact-us) - [Disclaimer](https://ausvaxsafety.org.au/disclaimer) - [Privacy](https://ausvaxsafety.org.au/privacy) - [Accessibility](https://ausvaxsafety.org.au/accessibility) AusVaxSafety receives funding from the Australian Government NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 \\| Fax (612) 9845 1418 \\| ABN 53 188 579 090 We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn. Copyright © 2026 AusVaxSafety. All rights reserved [![vaccine](https://ausvaxsafety.org.au/sites/default/files/inline-images/vaccine-safety-net-logo-2.png)](https://vaccinesafetynet.org/) Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety. ## Subscribe to our newsletter for immunisation professionals Stay updated with the latest from NCIRS - [Contact Us](https://ausvaxsafety.org.au/contact-us) - [Disclaimer](https://ausvaxsafety.org.au/disclaimer) - [Privacy](https://ausvaxsafety.org.au/privacy) - [Accessibility](https://ausvaxsafety.org.au/accessibility) ##### Subscribe to our newsletter for immunisation professionals Stay updated with the latest from ausvax NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 \\| Fax (612) 9845 1418 \\| ABN 53 188 579 090 ![](https://ausvaxsafety.org.au/sites/default/files/inline-images/vaccine-safety-net-logo-2.png) Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety. We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Readable Markdown	More than 60 million doses of COVID-19 vaccines have now been administered in Australia. The safety of these vaccines is monitored on an ongoing basis and while there are some commonly reported side effects, reports of serious side effects are extremely rare. ### Common side effects Like all medicines used in Australia, COVID-19 vaccines can cause mild side effects, but not everyone gets them. Most side effects are mild and short-lived, with the vast majority of people affected recovering within 3 days. Common side effects include: - pain at injection site - feeling tired - headache - aches and pain - fever and chills You can take pain relief medication such as paracetamol to help relieve these symptoms. [Access the latest COVID-19 vaccine short-term common side effects data here](https://ausvaxsafety.org.au/safety-data/covid-19-vaccines) It can take up to [12 days after the first dose](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-your-vaccination/after) of the vaccine for your body to produce antibodies to partially protect you, and [7–14 days after the second dose](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-your-vaccination/after) to reach the optimal level of protection provided by the vaccine. You cannot catch COVID-19 from getting your vaccine; however, if you develop COVID-19-like symptoms any time after your vaccination, it is important that you still get tested and follow public health advice. A booster dose is recommended [3 months after your second dose](https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/getting-your-vaccination/booster-doses) to make sure the protection from the first 2 doses is even stronger and longer lasting. ### Extremely rare side effects Serious or allergic reactions to vaccines are extremely rare. Although serious allergic reactions usually occur within 15 minutes of receiving a vaccine, there are some very rare conditions that have been linked to COVID-19 vaccines that can occur later after vaccination. ##### Blood clots (Thrombosis with thrombocytopenia syndrome – TTS) Thrombosis with thrombocytopenia syndrome (TTS) has been found to be causally associated with the AstraZeneca COVID-19 vaccine. This condition is very rare, with[2 cases out of every 100,000 people](https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report/current) after a first dose AstraZeneca vaccine and 3 cases out of every million people after a second dose of AstraZeneca vaccine reported in Australia. TTS involves the formation of blood clots (thrombosis) by platelets in body places where blood clots should not occur, such as the brain, abdomen, chest and legs, preventing blood flowing normally through those parts of the body. Because the platelets are used up in the formation of these clots, it leads to a decrease in platelets (thrombocytopenia) in the bloodstream, preventing them from doing their normal function. Thrombocytopenia can lead to excessive bleeding if blood cannot form clots where it is needed. Symptoms of TTS most commonly develop 4 to 30 days after an adenovector viral vaccine such as the AstraZeneca vaccine. The condition is not found to be associated with mRNA vaccines such as Pfizer and Moderna vaccines. Early treatment for TTS can prevent serious complications. It is therefore important for people with early symptoms of TTS to get medical attention as soon as possible. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have: - severe or persistent headache that does not go away after taking pain relief medication - blurred vision, loss of power or sensation, confusion or seizures - shortness of breath - abdominal pain that does not go away after taking pain relief medication - chest pain - leg pain or leg swelling - unusual bruising or pinpoint spots (petechiae) on skin that can not be explained from trauma. More detailed information on TTS is available at the links below: - [Department of Health, Disability and Ageing AstraZeneca COVID-19 vaccination information sheet](https://www.health.gov.au/resources/publications/covid-19-vaccination-information-on-vaxzevria-astrazeneca-covid-19-vaccine) - [Reported cases of TTS in Australia – TGA COVID-19 weekly vaccine safety reports](https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report) - [Joint statement from the Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on TTS and the use of COVID-19 Vaccine AstraZeneca](https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca) - [Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca](https://www.health.gov.au/resources/publications/covid-19-vaccination-weighing-up-the-potential-benefits-against-risk-of-harm-from-covid-19-vaccine-astrazeneca) - [AusVaxSafety Adverse event of special interest (AESI) follow-up program - TTS](https://ausvaxsafety.org.au/aesi-follow-program/study-arm-1-thrombosis-thrombocytopenia-syndrome) ##### Heart inflammation (myocarditis and pericarditis) In rare instances, myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the outer lining of the heart) have been reported by individuals after receiving an mRNA COVID-19 vaccine – Pfizer or Moderna. Most cases typically happen within 10 days of vaccination and occur more commonly after the second dose in men aged under 30 years. Most people have mild symptoms and recover well. In Australia, [1–2 cases out of every 100,000 people](https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report/current) after receiving the Pfizer vaccine have been reported. Contact your doctor or healthcare professional as soon as possible or go directly to a hospital if you have: - chest pain - pressure or discomfort in the chest - irregular, skipped heartbeats or ‘fluttering’ - fainting - shortness of breath - pain when breathing. More detailed information on myocarditis and pericarditis is available at the links below: - [Department of Health, Disability and Ageing guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines](https://www.health.gov.au/resources/publications/covid-19-vaccination-guidance-on-myocarditis-and-pericarditis-after-mrna-covid-19-vaccines) - [Reported cases of myocarditis and pericarditis in Australia – TGA COVID-19 weekly vaccine safety reports](https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report) ### COVID-19 Vaccine Side Effects Symptom Checker If you think you may be experiencing side effects following your COVID-19 vaccination, you can check these and get information on what to do next on the healthdirect COVID-19 vaccine Side Effects Symptom Checker below. [healthdirect COVID-19 vaccine Side Effects Symptom Checker](https://www.healthdirect.gov.au/covid-19-vaccine-side-effect-checker) Last updated May 2025
Shard	133 (laksa)
Root Hash	15465543789884751333
Unparsed URL	au,org,ausvaxsafety!/covid-19-vaccine-side-effects s443